NI201000176A - 2,6-DIAMINO-PYRIMIDIN-5-IL-CARBOXAMIDES AS INHIBITORS OF SYK OR JAK KINASES. - Google Patents

2,6-DIAMINO-PYRIMIDIN-5-IL-CARBOXAMIDES AS INHIBITORS OF SYK OR JAK KINASES.

Info

Publication number
NI201000176A
NI201000176A NI201000176A NI201000176A NI201000176A NI 201000176 A NI201000176 A NI 201000176A NI 201000176 A NI201000176 A NI 201000176A NI 201000176 A NI201000176 A NI 201000176A NI 201000176 A NI201000176 A NI 201000176A
Authority
NI
Nicaragua
Prior art keywords
syk
inhibitors
methods
carboxamides
pyrimidin
Prior art date
Application number
NI201000176A
Other languages
Spanish (es)
Inventor
M Bauer Shawn
J Jia Zhaozhong
Song Yonghong
Xu Qing
Mehrotra Mukund
W Rose Jack
Huang Wolin
Venkataramani Chandrasekar
Pandey Anjali
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of NI201000176A publication Critical patent/NI201000176A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La presente invención se dirige a compuestos de la Fórmula I-II y tautómeros, sales o estereoisómeros farmacéuticamente aceptables de la misma que son inhibidores de syk y/o JAK quinasas. La presente invención también se dirige a intermediarios usados para realizar dichos compuestos, a la preparación de dicho compuesto, composiciones farmacéuticas que contienen dicho compuesto, métodos de inhibición de syk y/o JAK quinasa, métodos para la inhibición de agregación de plaquetas, y métodos para evitar o tratar una cantidad de enfermedades mediadas, al menos en parte, por la actividad syk y/o JAK quinasa, como por ejemplo trombosis y Linfoma no- Hodgkin.The present invention is directed to compounds of Formula I-II and pharmaceutically acceptable tautomers, salts or stereoisomers thereof which are inhibitors of syk and / or JAK kinases. The present invention is also directed to intermediates used to make said compounds, to the preparation of said compound, pharmaceutical compositions containing said compound, methods of inhibiting syk and / or JAK kinase, methods for inhibiting platelet aggregation, and methods to prevent or treat a number of diseases mediated, at least in part, by syk and / or JAK kinase activity, such as thrombosis and Non-Hodgkin's Lymphoma.

NI201000176A 2008-04-16 2010-10-15 2,6-DIAMINO-PYRIMIDIN-5-IL-CARBOXAMIDES AS INHIBITORS OF SYK OR JAK KINASES. NI201000176A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US4539908P 2008-04-16 2008-04-16
US4541708P 2008-04-16 2008-04-16
US4540608P 2008-04-16 2008-04-16
US12034108P 2008-12-05 2008-12-05
US12034408P 2008-12-05 2008-12-05
US12034808P 2008-12-05 2008-12-05

Publications (1)

Publication Number Publication Date
NI201000176A true NI201000176A (en) 2011-08-08

Family

ID=43570275

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201000176A NI201000176A (en) 2008-04-16 2010-10-15 2,6-DIAMINO-PYRIMIDIN-5-IL-CARBOXAMIDES AS INHIBITORS OF SYK OR JAK KINASES.

Country Status (18)

Country Link
AU (1) AU2009251863B2 (en)
BR (1) BRPI0910560B8 (en)
CO (1) CO6331433A2 (en)
CY (1) CY1118559T1 (en)
DK (1) DK2321283T3 (en)
ES (1) ES2597441T3 (en)
GT (1) GT201000298A (en)
HK (1) HK1158179A1 (en)
HU (1) HUE031638T2 (en)
IL (3) IL208637A (en)
LT (1) LT2321283T (en)
MX (1) MX353206B (en)
NI (1) NI201000176A (en)
NZ (1) NZ589314A (en)
PL (1) PL2321283T3 (en)
PT (1) PT2321283T (en)
SI (1) SI2321283T1 (en)
ZA (1) ZA201007045B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102083800A (en) 2008-06-27 2011-06-01 阿维拉制药公司 Heteroaryl compounds and uses thereof
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
AU2013202496B2 (en) * 2008-06-27 2016-08-04 Celgene Car Llc Heteroaryl compounds and uses thereof
EP3144298A1 (en) 2010-08-10 2017-03-22 Celgene Avilomics Research, Inc. Besylate salt of a btk inhibitor
US9561228B2 (en) 2013-02-08 2017-02-07 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
EP3179858B1 (en) 2014-08-13 2019-05-15 Celgene Car Llc Forms and compositions of an erk inhibitor
CN114196651B (en) * 2021-12-15 2023-06-30 中国林业科学研究院亚热带林业研究所 New application of D6 protein kinase D6PKL2

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1054004B1 (en) * 1997-12-15 2008-07-16 Astellas Pharma Inc. Novel pyrimidine-5-carboxamide derivatives
WO2004002964A1 (en) * 2002-06-28 2004-01-08 Yamanouchi Pharmaceutical Co., Ltd. Diaminopyrimidinecarboxa mide derivative
AU2007276369A1 (en) * 2006-07-21 2008-01-24 Novartis Ag 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as JAK kinases inhibitors

Also Published As

Publication number Publication date
HUE031638T2 (en) 2017-07-28
CY1118559T1 (en) 2017-07-12
IL208637A0 (en) 2010-12-30
HK1158179A1 (en) 2012-07-13
AU2009251863A1 (en) 2009-12-03
BRPI0910560B1 (en) 2023-01-24
IL251655B (en) 2020-05-31
ZA201007045B (en) 2012-08-29
IL251655A0 (en) 2017-06-29
MX2010011464A (en) 2014-06-16
GT201000298A (en) 2014-05-07
AU2009251863B2 (en) 2014-09-25
BRPI0910560A2 (en) 2021-04-27
SI2321283T1 (en) 2017-01-31
AU2009251863A2 (en) 2011-06-09
MX353206B (en) 2018-01-08
BRPI0910560B8 (en) 2023-03-21
DK2321283T3 (en) 2016-10-31
LT2321283T (en) 2016-12-12
IL274522A (en) 2020-06-30
ES2597441T3 (en) 2017-01-18
NZ589314A (en) 2012-10-26
PL2321283T3 (en) 2017-01-31
IL208637A (en) 2017-04-30
CO6331433A2 (en) 2011-10-20
PT2321283T (en) 2016-10-19

Similar Documents

Publication Publication Date Title
DOP2010000310A (en) 2,6-DIAMINO-PYRIMIDIN-5-IL-CARBOXAMIDS AS SYK OR JAK KINASAS INHIBITORS
NZ588830A (en) Inhibitors of protein kinases
BR112015028501B8 (en) BIPYRAZOLE DERIVATIVE COMPOUNDS, THEIR SALTS, COMPOSITION COMPRISING THE COMPOUND OR THE SALT, METHOD FOR IN VITRO INHIBITION OF A JAK1 ACTIVITY, AND PROCESS FOR PREPARING PHOSPHORIC ACID SALT
BR112014004504A2 (en) "compound as c-kit kinase inhibitor, its use, pharmaceutical composition, and medicament for the treatment of a kinase mediated disease"
NI201000176A (en) 2,6-DIAMINO-PYRIMIDIN-5-IL-CARBOXAMIDES AS INHIBITORS OF SYK OR JAK KINASES.
EA201001618A1 (en) INHIBITORS SYK PROTEINKINAZ
BR112015022643A2 (en) dihydropyrrolpyridinone inhibitors
CO7160119A2 (en) Imidazo [1,2-b] pyridazine derivatives as a kinase inhibitor
TR201802944T4 (en) DERIVATIVES OF AZAINDAZOL OR DIAZAINDAZOL
ECSP12011645A (en) JAK DE PIRAZOLOPIRIMIDINA INHIBITING COMPOUNDS AND METHODS
NI201000145A (en) DERIVATIVES OF IMIDAZINE - [1, 2-b] - PYRIDAZINE FOR THE TREATMENT OF DISEASE MEDIATED BY TYROSINE KINASE C-MET.
EA201500182A1 (en) 4-METHYL-2,3,5,9,9b-PENTAASACYCLOPENT [a] NAFTAIL
EA201692506A2 (en) ANTI-FLY VIRUS REPLICATION INHIBITORS
ECSP12011880A (en) INHIBITORS OF N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXYLASE
NI201000050A (en) DERIVATIVES OF PIRROLO [2, 3-D] PYRIMIDINE AS INHIBITORS OF PROTEIN KINASES B.
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
BR112014006297A2 (en) cathepsin c n- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors, their uses, and pharmaceutical composition
UY30282A1 (en) CHEMICAL COMPOUNDS
CO7131360A2 (en) Novel substituted cyclic n-pyridinyl amides as kinase inhibitors
DOP2013000243A (en) ACETIL-COA CARBOXILASA REPLACED INHIBITORS
BR112013017362A2 (en) compound of formula (i), process for preparing a compound of formula (i), pharmaceutical composition and innovative compounds, methods and uses
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
GEP20166481B (en) (crystalline forms of hydrochloride salt of (4a-r, 9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2, 3, 4, 4a, 9, 9a-hexa- hydro-1h-indeno [2, 1-b] pyridine-6-carbonitrile and their use as hsd 1 inhibitors
GB201302704D0 (en) Therapeutic compounds
MX341577B (en) Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mtor inhibitors.